Preview

Научно-практическая ревматология

Расширенный поиск

Эффективность и безопасность сарилумаба (полностью человеческие моноклональные антитела к рецептору интерлейкина 6) при ревматоидном артрите: новые данные

https://doi.org/10.14412/1995-4484-2019-564-57

Полный текст:

Аннотация

Ревматоидныйартрит (РА) – иммуновоспалительное (аутоиммунное) ревматическое заболевание неизвестной этиологии, характеризующееся хроническим эрозивным артритом (синовитом) и системным  поражением внутренних  органов,  приводящее к ранней инвалидности и сокращению продолжительности жизни пациентов.  В спектре «провоспалительных» цитокинов, принимающих участие в патогенезе РА, большое внимание уделяется изучению роли интерлейкина 6 (ИЛ6). Внедрение в клиническую практику моноклональных антител к ИЛ6-рецепторам тоцилизумаба  и сарилумаба,  ингибирующих активность  этого цитокина, является важным шагом на пути совершенствования терапии РА. В обзоре рассмотрены данные основных  рандомизированных контролируемых исследований, касающихся эффективности и безопасности сарилумаба при РА, и обсуждены перспективы применения сарилумаба в терапии этого заболевания.

Об авторах

Е. Л. Насонов
Научно-исследовательский институт ревматологии им. В.А. Насоновой; Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)
Россия

Насонов Евгений Львович - научный руководитель ФГБНУ НИИР им. В.А. Насоновой, академик  РАН, профессор, доктор медицинских наук.

115522, Москва, Каширское шоссе, 34А; 119991 Москва, ул. Трубецкая, 8, стр. 2.



А. М. Лила
Научно-исследовательский институт ревматологии им. В.А. Насоновой; Российская медицинская академия непрерывного профессионального образования Минздрава России
Россия

115522, Москва, Каширское шоссе, 34А; 125993, Москва, ул. Баррикадная, 2/1.



Список литературы

1. Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331.

2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New Eng J Med. 2012;365:2205-19. doi: 10.1056/NEJMra1004965

3. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 22;388(10055):2023-38. doi: 10.1016/S0140-6736(16)30173-8

4. Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва, ИМА-ПРЕСС; 2013.

5. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338-48. doi: 10.1016/S0140-6736(17)31491-5

6. Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-19. doi: 10.14412/1995-4484-2017-409-419

7. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555

8. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328-37. doi: 10.1016/S0140-6736(17)31472-1

9. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;15:448-57. doi: 10.1038/ni1117-1271b

10. Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-9. doi: 10.14412/1995-4484-2017-590-599

11. Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17(6):395-412. doi: 10.1038/nrd.2018.45

12. Rubbert-Roth A, Furst DE, Nebesky JM, et al. A review of recent advances using tocilizumab in the treatment of rheumatic diseases. Rheumatol Ther. 2018;5(1):21-42. doi: 10.1007/s40744-018-0102-x

13. Lamb YN, Deeks ED. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis. Drugs. 2018;78(9):929-40. doi: 10.1007/s40265-018-0929-z

14. McCarty D, Robinson A. Efficacy and safety of sarilumab in patients with active rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(3):61-7. doi: 10.1177/1759720X17752037

15. Genentech Inc. Actemra (package insert). California: Genentech Inc, https://www.gene.com/download/pdf/actemra_prescribing.pdf (2017, accessed 15 September 2017).

16. Regeneron Pharmaceuticals Inc / Sanofi-aventis US LLC. Kevzara (package insert). New York/New Jersey: Regeneron Pharmaceuticals Inc / Sanofi-aventis US LLC, http://products.sanofi.us/kevzara/kevzara.pdf (2017, accessed 10 September 2017).

17. Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ra in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results for the randomized SARIK-RA-MOBILITY part A trial. Ann Rheum Dis. 2014;73:1626-34. doi: 10.1136/annrheumdis-2013-204405

18. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheum. 2015;67:1424-37. doi: 10.1002/art.39093

19. Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheum. 2017;69:277-90. doi: 10.1002/art.39944

20. Burmester GR, Lin YL, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomized, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76:840-7. doi: 10.1136/annrheumdis-2016-210310

21. Wells AF, Parrino J, Mangan EK, et al. Immunogenicity of sarilumab monotherapy in patients with rheumatoid arthritis who were inadequate responders or intolerant to disease-modifying antirheumatic drugs. Rheumatol Ther. 2019 May 14. doi: 10.1007/s40744-019-0157

22. Emery P, Rondon J, Parrino J, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2018 Dec 19. doi: 10.1093/rheumatology/key361

23. Genovese MC, van Adelsberg J, Fan C, et al.; EXTEND study investigators. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology (Oxford). 2018;57(8):1423-31. doi: 10.1093/rheumatology/key121

24. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37. doi: 10.1002/art.21519

25. Emery P, Pope JE, Kruger K, et al. Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: A systematic review. Adv Ther. 2018;35(10):1535-63. doi: 10.1007/s12325-018-0757-2

26. Burmester GR, St John G, Iglesias-Rodrigues M, et al. Switching from adalimumab to sarilumasb is associated with comparable efficacy bit lower functional improvement versus comtinous earilumab monotherapy thtough 48-week open-label extension (OLE) of the phase III MONARCH rial. Ann Rheum Dis. 2018;77(Suppl 2):952-3. doi: 10.1136/annrheumdis-2018-eular.1372

27. Tanaka Y, Wada K, Takahashi Y, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther. 2019;21(1):79. doi: 10.1186/s13075-019-1856-4

28. Kameda H, Wada K, Takahashi Y, et al. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA). Mod Rheumatol. 2019 Jul 24. doi: 10.1080/14397595.2019.1639939

29. Genovese MC, Fleischmann R, Mangan E, et al. Efficacy and safety of Sarilumab in subgroups of patients with rheumatoid arthritis from 2 phase 3 studies [abstract]. Arthritis Rheum. 2016;68(suppl 10). Available from: https://acrabstracts.org/abstract/efficacy-and-safety-of-sarilumab-in-subgroups-of-patients-with-rheumatoid-arthritis-from-2-phase-3-studies/

30. Genovese MC, van der Heijde D, Lin Y, et al. Long-term safety and efficacy of sarikumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open. 2019;5:e000887. doi: 10:1136/rmdopen-2018-000887

31. Burmester GR, Lin Y, St John G, et al. Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csDMARD in patients with rheumatoid arthritis. Ann Rheum Dis. 2018. doi: 10.1136/qnnrheumdis-20180eular.SAT0172

32. Curtis JR, Lin Y, Thangsvelu K, et al. Withdrawal of conventional synthetic disease-modifying antitheumatic drugs in the sarilumab open-label EXTEND study: efficacy and safety analysis. Ann Rheum Dis. 2019;78(Suppl 2):702-3. doi: 10.1136/annrheumdis-2019-eular.740

33. Emery P, van Hoogstraten H, Jayawardena S, et al. Efficacy of Sarilumab in Patients with Rheumatoid Arthritis Who Previously Received Sarilumab or Tocilizumab [abstract]. Available from: https://acrabstracts.org/abstract/efficacy-of-sarilumab-in-patients-with-rheumatoid-arthritis-who-previously-received-sarilumab-or-tocilizumab/

34. Vershueren P, Emery P, van Hoogstraten H, et al. Efficaсy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab. Ann Rheum Dis. 2018;77(Suppl.2):327. https://doi.org/10.1136/annrheumdis-2018-eular.1376

35. Насонов ЕЛ, Станислав МЛ, Раскина ТА и др. Эффективность и безопасность сарилумаба в комбинации с метотрексатом у пациентов с активным ревматоидным артритом и неадекватным эффектом монотерапии метотрексатом (результаты исследования III фазы по протоколу MOBILITY). Научно-практическая ревматология. 2019;57(2):142-8. doi: 10.14412/1995-4484-2019-142-148

36. Food and Drug Administration (2009) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf

37. Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019. doi: 10.1136/rmdopen-2014-000019

38. Fautrel B, Alten R, Kirkham B, et al. Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int. 2018;38(6):935-47. doi: 10.1007/s00296-018-4005-5

39. Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients' lives. Clin Exp Rheumatol. 2010;28:S32-40.

40. Rendas-Baum R, Bayliss M, Kosinski M, et al. Measuring the effect of therapy in rheumatoid arthritis clinical trials from the patient's perspective. Curr Med Res Opin. 2014;30:1391-403. doi: 10.1185/03007995.2014.896328

41. Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44:123-30. doi: 10.1016/j.semarthrit.2014.05.001

42. Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3):263-71. doi: 10.14412/1995-4484-2018-263-271

43. Choy EHS, Calabrese LH. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford). 2018;57(11):1885-95. doi: 10.1093/rheumatology/kex391

44. Каратеев А.Е., Насонов Е.Л. Хроническая боль и центральная сенситизация при иммуновоспалительных ревматических заболеваниях: патогенез, клинические проявления, возможность применения таргетных базисных противовоспалительных препаратов. Научно-практическая ревматология. 2019;57(2):197-209. doi: 10.14412/1995-4484-2019-197-209

45. Лисицына ТА, Вельтищев ДЮ, Серавина ОФ и др. Провоспалительные цитокины и депрессия при ревматоидном артрите. Научно-практическая ревматология. 2013;51(3):261-6. doi: 10.14412/1995-4484-2013-1498

46. Лисицына ТА, Вельтищев ДЮ, Лила АМ, Насонов ЕЛ. Интерлейкин 6 как патогенетический фактор, опосредующий формирование клинических проявлений, и мишень для терапии ревматических заболеваний и депрессивных расстройств. Научно-практическая ревматология. 2019;57(3):318-27. doi: 10.14412/1995-4484-2019-318-32747.

47. Crotti C, Biggioggero M, Becciolini A, Favalli EG. Sarilumab: patient-reported outcomes in rheumatoid arthritis. Patient Relat Outcome Meas. 2018;9:275-84. doi: 10.2147/PROM.S147286

48. Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18:19. doi: 10.1186/s13075-016-1096-9

49. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43(7):1478-87. doi: 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M

50. Gossec L, Strand V, Proudfoot C, et al. Effects of Sarilumab on rheumatoid arthritis as reported by patients using the rheumatoid arthritis impact of disease scale. J Rheumatol. 2019 Mar 15. doi: 10.3899/jrheum.180904

51. Dougados M, Brault Y, Logeart I, et al. Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID). Arthritis Res Ther. 2012;14(3):R129. doi: 10.1186/ar3859

52. Gullick NJ, Scott DL. Rheumatoid arthritis: clinical utility of the RAID (RA Impact of Disease) score. Nat Rev Rheumatol. 2011;7:499-500. doi: 10.1038/nrrheum.2011.105

53. Heiberg T, Austad C, Kvien TK, Uhlig T. Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to other patient-reported outcomes in a register of patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:1080-2. doi: 10.1136/ard.2010.143032

54. Gossec L, Paternotte S, Aanerud GJ, et al. Finalisation and validation of the Rheumatoid Arthritis Impact of Disease score, a patient-derived composite measure of impact of rheumatoid arthritis: A EULAR initiative. Ann Rheum Dis. 2011;70:935-42. doi: 10.1136/ard.2010.142901

55. Strand V, Gossec L, Proudfoot CWJ, et al. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Arthritis Res Ther. 2018;20(1):129. doi: 10.1186/s13075-018-1614-z

56. Gossec L, Boklage S, St John G, et al. Pain is improved in around 50% of patients and fatigue in 40% of patients with rheumatoid arthritis treated with sarilumab in the target, mobility and monarch trials [abstract]. Arthritis Rheum. 2018;70(suppl 10). Available from: https://acrabstracts.org/abstract/pain-is-improved-in-around-50-of-patients-and-fatigue-in-40-of-patients-with-rheumatoid-arthritis-treated-with-sarilumab-in-the-target-mobility-and-monarch-trials/

57. Choy E, Freemantle N, Proudfoot C, et al. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. RMD Open. 2019 18;5(1):e000798. doi: 10.1136/rmdopen-2018-000798

58. Choy E, Freemantle N, Proudfoot C, et al. Indirect treatment comparison of the efficacy and safety of Sarilumab monotherapy in rheumatoid arthritis patients with inadequate response to conventional disease-modifying antirheumatic drugs. Adv Ther. 2019;36(4):817-27. doi: 10.1007/s12325-019-00912-x

59. Boyapati A, Msihid J, Fiore S, et al. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Arthritis Res Ther. 2016;18:225.

60. Gabay C, Msihid J, Zilberstein M, et al. Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study. RMD Open. 2018;4(1):e000607. doi: 10.1136/rmdopen-2017-000607

61. Dennis G, Holweg CT, Kummerfeld SK, et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther. 2014;16:R90. doi: 10.1186/ar4555

62. Choi IY, Gerlag DM, Herenius MJ, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:499-505. doi: 10.1136/annrheumdis-2013-203923

63. Ferraccioli G, Tolusso B, Bobbio-Pallavicini F, et al. Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. PLoS One. 2012;7:e40362. doi: 10.1371/journal.pone.0040362

64. Han BK, Kuzin I, Gaughan JP, et al. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: A pilot, prospective study. Arthritis Res Ther. 2016;18:93. doi: 10.1186/s13075-016-0995-0

65. Koczan D, Drynda S, Hecker M, et al. Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther. 2008;10:R50. doi: 10.1186/ar2419

66. Karsdal MA, Schett G, Emery P, et al. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum. 2012;42:131-9. doi: 10.1016/j.semarthrit.2012.01.004

67. Boumans MJ, Thurlings RM, Yeo L, et al. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis. 2012;71:108-13. doi: 10.1136/annrheumdis-2011-200198

68. Yasunori K, Masaaki T, Tetsuyuki N, et al. Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis. Clin Rheumatol. 2008;27:1093-101. doi: 10.1007/s10067-008-0870-8

69. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58:1299-309. doi: 10.1002/art.23417

70. Boyapati A, Msihid J, Schwartzman S, et al. High baseline serum IL-6 identies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response [abstract]. Arthritis Rheum. 2018 Oct;70(Suppl 10). Available from: https://acrabstracts.org/abstract/high-baseline-serum-il-6-identifies-a-subgroup-of-rheumatoid-arthritis-patients-with-rapid-joint-damage-and-clinical-progression-and-predicts-increased-sarilumab-treatment-response/

71. Wang J, Devenport J, Low JM, et al. Relationship between base-line and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res. 2016;68:882-5. doi: 10.1002/acr.22765

72. Burmester GR, Hagino O, Dong Q, et al. Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA) [abstract]. Arthritis Rheum. 2018;70 (suppl 10). Available from: https://acrabstracts.org/abstract/unique-changes-in-hemoglobin-with-sarilumab-versus-adalimumab-are-independent-of-better-disease-control-in-patients-with-rheumatoid-arthritis-ra/

73. Genovese MC, Fleischmann R, Hagino O, et al. The effect of Sarilumab in combination with dmards on fasting glucose and glycosylated hemoglobin in patients with rheumatoid arthritis with and without diabetes [abstract]. Arthritis Rheum. 2017;69(Suppl 10).

74. Winthrop KL. Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. Rheum Dis Clin North Am. 2012;38(4):727-45. doi: 10.1016/j.rdc.2012.08.019

75. Fleischmann R, Genovese MC, Lin Y, et al. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. Rheumatology (Oxford). 2019 Jul 15. pii: kez265. doi: 10.1093/rheumatology/kez265

76. Genovese MC, Rubbert-Roth A, Smolen JS, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol. 2013;40:768-80. doi: 10.3899/jrheum.120687

77. Kovalenko P, Paccaly A, Boyapati A, et al. Pharmacodynamic (PD) model of neutrophil margination to describe transient effect of single-dose sarilumab on absolute neutrophil count (ANC) in patients with rheumatoid arthritis (RA). J Pharmacokinet Pharmacodyn. 2017;44(Suppl 1):S11-S143. Abstract T-033.

78. Lok LSC, Farahi N, Juss JK et al. Effects of tocilizumab on neutrophil function and kinetics. Eur J Clin Invest. 2017;47:736-45. doi: 10.1111/eci.12799

79. Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology. 2014;53:1321-31. doi: 10.1093/rheumatology/keu035

80. Choy E, Ganeshalingam K, Semb AG, et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology. 2014;53:2143-54. doi: 10.1093/rheumatology/keu224

81. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326-32. doi: 10.1136/annrheumdis-2014-205675

82. Liao KP, Liu J, Lu B, et al. Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients. Arthritis Rheum. 2015;67:2004-10. doi: 10.1002/art.39165

83. Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev. 2014;22:147-51. doi: 10.1097/CRD.0000000000000021

84. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118:145-56. doi: 10.1161/CIRCRESAHA.115.306656

85. Насонов ЕЛ, Попкова ТВ. Противовоспалительная терапия атеросклероза – вклад и уроки ревматологии. Научно-практическая ревматология. 2017;55(5):465-73. doi: 10.14412/1995-4484-2017-465-473

86. Charles-Schoeman C, St John G, Leher H, et al. The relationship between lipid profile changes and inflammation across the Phase 3 sarilumab rheumatoid arthritis (RA) development programme. Rheumatology. 2019;58(Suppl 3):kez110.062, E064. doi: 10.1093/rheumatology/kez110.062

87. Curtis JR, Lanas A, John A, et al. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res. 2012;64:1819-28. doi: 10.1002/acr.21764

88. Gout T, Ostor AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol. 2011;30:1471-4. doi: 10.1007/s10067-011-1827-x

89. Scott IC, Hider SL, Scott DL. Thromboembolism with Janus kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk? Drug Saf. 2018;41:645-53. doi: 10.1007/s40264-018-0651-5

90. Ungprasert P, Srivali N, Spanuchart I, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2014;33:297-304. doi: 10.1007/s10067-014-2492-7

91. Сатыбалдыева МА. Ревматоидный артрит и венозные тромбоэмболические осложнения. Научно-практическая ревматология. 2016;54(4):456-62. doi: 10.14412/1995-4484-2016-456-462

92. Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. doi: 10.14412/1995-4484-2019-8-16

93. Gadina M, Johnson C, Schwartz D, et al. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. J Leukoc Biol. 2018;104(3):499-514. doi: 10.1002/JLB.5RI0218-084R

94. Qu X, Tang Y, Hua S. Immunological approaches towards cancer and inflammation: A Cross Talk. Front Immunol. 2018;9:563. doi: 10.3389/fimmu.2018.00563

95. Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234-48. doi: 10.1038/nrclinonc.2018.8

96. Genovese MC, Kremer JM, van Vollenhoven RF et al.Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis. Arthritis Rheum. 2017;69:1751-61. doi: 10.1002/art.40176

97. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77. doi: 10.1136/annrheumdis-2016-210715

98. Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. 464 с.

99. Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72(12):1897-904. doi: 10.1136/annrheumdis-2013-203485

100. Schaeverbeke T, Truchetet ME, Kostine M, et al. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology (Oxford). 2016;55(2):210-20. doi: 10.1093/rheumatology/kev277

101. Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017;13(12):707-18. doi: 10.1038/nrrheum.2017


Для цитирования:


Насонов Е.Л., Лила А.М. Эффективность и безопасность сарилумаба (полностью человеческие моноклональные антитела к рецептору интерлейкина 6) при ревматоидном артрите: новые данные. Научно-практическая ревматология. 2019;57(5):564-577. https://doi.org/10.14412/1995-4484-2019-564-57

For citation:


Nasonov E.L., Lila A.M. The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence. Rheumatology Science and Practice. 2019;57(5):564-577. (In Russ.) https://doi.org/10.14412/1995-4484-2019-564-57

Просмотров: 227


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)